# Trade Mark Journal No.2026/034 21 August 2026

## UK00004426927 6 August 2026 (5)

FUSELPA

International priority date claimed: 24 June 2026 (United States of America) (99903795)

Class 5
  Antivirals; Antibodies for medical purposes; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, autoimmune diseases, solid organ transplant rejection, autoinflammatory diseases, blood diseases, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, Alzheimer’s disease, autism spectrum disorder, and musculoskeletal and skin diseases; Biological preparations for the treatment of cancer.

Bristol-Myers Squibb Company

Representative: Sipara Limited